Period2 Jun 2024 → 3 Jun 2024

Media coverage

3

Media coverage

  • TitlePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated
    Media name/outletMarket News Publishing
    Country/TerritoryUnited States
    Date3/06/24
    PersonsJoshua Brody
  • TitlePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
    Media name/outletBioSpace
    Country/TerritoryUnited States
    Date2/06/24
    URLct.moreover.com/?a=53965945455&p=1gw&v=1&x=WuVmndUwCjtKts8OyvKHhA
    PersonsJoshua Brody
  • TitleGenmab: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date2/06/24
    PersonsJoshua Brody